Skip To Main Content
Chandran Nair on Muck Rack

Chandran Nair

Hong Kong
As seen in: QOSHE, CNN, MSN, MSN Canada, The New York Times, Financial Times, HuffPost, Nature, The Guardian, The Washington Post, TIME and
Founder and CEO of Global Institute For Tomorrow (GIFT), author, speaker. Order my latest book here: Understanding China a.co/d/05qoZQ6W
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Chandran

Contact Chandran, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

KL's devastation creep: Who profits from the abuse of our city?

|
By Chandran Nair
| Malaysiakini Verified
COMMENT | Part One of this series set out the civic failures that have led to Kuala Lumpur’s rising temperatures and falling standards: no science, no press, and no public voice. The natural response for many of KL’s inhabitants is passivity and resignation, especially when all the people in positions of authority who are responsible for the rising heat, the mismanaged flood control, the exploding pipeline, the sold-off green lungs have given a speech about making KL a world-class city.
Open in Who Shared Issue with article?

Built for slow burn: Kuala Lumpur's unbreakable heat

|
By Chandran Nair
| Malaysiakini Verified
COMMENT | The Star recently published a piece asking whether Kuala Lumpur sits on one of the world's most intense urban heat islands. The answer, confirmed by peer-reviewed science and satellite data, was yes - and increasingly so. The data is astounding on its own. Yet that an article like that was even published is a symptom of a deeper problem: in a city governed seriously, skyrocketing urban heat would not be a "true or false" question requiring a newspaper to fact-check foreign studies.
Open in Who Shared Issue with article?

Enabling access to talicabtagene autoleucel in relapsed/refractory B-cell malignancies; multicenter real-world evidence on delivery, efficacy and safety

|
By Atharva Karulkar, Hasmukh Jain, Neeraj Sidharthan, Dinesh Bhurani, Sameer Melinkeri, Pavan Kumar Boyella, Prashant Mehta, Esha Kaul, Sanket R. Shah, Chandran Nair, Rahul Bhargava, Bhausaheb Bagal, Lingaraj Nayak, Alok Shetty, Hari Menon, Devanshi Kalra, Shalini Purwar, Nirali Shah, Terry Fry, Nitin Jain, Sattva Neelapu, Manju Sengar, Rahul Purwar, Jayachandran P. K, Rakesh Reddy Boya, Ram Abhinav, Smrithi Ravikumar, Jayashree Thorat
| Nature Verified
Abstract Talicabtagene autoleucel (tali-cel) is the first humanized CD19-directed CAR-T cell therapy approved in India for relapsed/refractory (r/r) B-cell acute lymphoblastic leukemia (B-ALL) and B-cell non-Hodgkin lymphoma (B-NHL). Here, we integrated clinical and manufacturing operations through a centralized coordination unit (CCU) and evaluated tali-cel implementation.
Open in Who Shared Issue with article?
See all 294 licensed articles (366 Total)